Commonwealth Equity Services LLC Acquires 3,045 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Commonwealth Equity Services LLC increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 39.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 10,814 shares of the medical equipment provider's stock after buying an additional 3,045 shares during the period. Commonwealth Equity Services LLC's holdings in Lantheus were worth $967,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of LNTH. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the third quarter valued at $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at about $27,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. World Investment Advisors LLC acquired a new stake in Lantheus in the third quarter worth approximately $60,000. Finally, Parkside Financial Bank & Trust boosted its stake in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,109 shares of company stock worth $6,110,806. Corporate insiders own 2.00% of the company's stock.

Lantheus Stock Performance

LNTH stock traded down $6.29 during midday trading on Friday, hitting $90.92. 1,158,346 shares of the company's stock were exchanged, compared to its average volume of 946,182. Lantheus Holdings, Inc. has a one year low of $58.46 and a one year high of $126.89. The company has a market cap of $6.23 billion, a PE ratio of 15.13 and a beta of 0.38. The stock's fifty day moving average price is $93.31 and its 200-day moving average price is $96.03.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

LNTH has been the topic of several analyst reports. JMP Securities reissued a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.